WHAT IS CLAIMED IS:

1. Use of a lysine specific demethylase (LSD) inhibitor and a cancer therapy agent in the manufacture of a medicament for treating or preventing a metastatic cancer, wherein the metastatic cancer comprises cancer stem cells (CSCs) and non-CSC tumor cells, wherein the LSD inhibitor inhibits proliferation, survival or viability of the CSCs, wherein the cancer therapy agent inhibits the proliferation, survival or viability of the non-CSC tumor cells, and wherein the CSCs have impaired or abrogated expression of the pluripotent stem cell marker Sox2 in which the CSC expresses Sox2 at a level or functional activity that is less than about 1/5 of the level or functional activity of Sox2 on a pluripotent stem cell, wherein the LSD inhibitor and the cancer therapy or agent are for concurrent administration.

2. A use according to claim 1, wherein the LSD inhibitor is a LSD1 inhibitor.

3. A use according to claim 1 or claim 2, wherein the LSD inhibitor is a selective LSD1 inhibitor.

4. A use according to any one of claims 1 to 3, wherein the cancer therapy agent is selected from chemotherapy, hormone ablation therapy, pro-apoptosis therapy and immunotherapy.

5. A use according to any one of claims 1 to 3, wherein the cancer therapy agent is selected from stem cell transplant and antibody therapy.

6. A use according to any one of claims 1 to 5, wherein the cancer therapy agent targets rapidly dividing cells or disrupts the cell cycle or cell division.

7. A use according to any one of claims 1 to 6, wherein the metastatic cancer is metastatic breast cancer.